Drug intelligence / Profile preview

IDC226

Development stage: Preclinical
Lead developer: Prestige Biopharma Innovative Discovery Centre
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

IDC226 is a preclinical-stage monoclonal antibody candidate developed by Prestige Biopharma (PBK) for the treatment of arthritis. The drug is being developed using the company's proprietary subcutaneous (SC) platform technology, which aims to enable high-concentration antibody delivery via subcutaneous injection, potentially improving patient convenience compared to intravenous administration. As of the latest pipeline updates, IDC226 is in the Proof of Concept (PoC) stage of preclinical development. The specific molecular target of the antibody has not been disclosed by the developer.

Beyond the preview

Go deeper on IDC226.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDC226.

Explore the full profile